CALGARY, Alberta, Nov. 20, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the filing on SEDAR (www.sedar.com) of the Notice of Meeting and Management Information Circular (the “Notice”) related to its Annual and Special Meeting of Shareholders (the “Meeting”) being held on Tuesday, December 22, 2020 commencing at approximately 1:00 pm (MT).
The Notice, outlining the matters to be considered at the Meeting, contains an important Cautionary Note on ‘In-Person’ Attendance. Shareholders are advised to read this note carefully in light of the rapidly evolving COVID-19 outbreak.
The Company strongly urges shareholders not to attend the Meeting in person as it can only safely accommodate a very limited number of attendees and, in order to mitigate potential risks to public health and safety, access to the Meeting will be limited to essential personnel and others entitled to attend the Meeting, subject to capacity and other restrictions.
As such, the Company has organized a webcast of the Meeting (details are set out below) whereby shareholders can listen to the Meeting live online. This is not a virtual meeting and shareholders cannot vote or ask questions as part of the Meeting; questions can be submitted in advance by emailing firstname.lastname@example.org.
The Company encourages shareholders to vote their shares at least forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays) prior to the Meeting (or any adjournment thereof) by following the instructions set out in the form of proxy or voting instruction form received by such shareholders.
Following the formal business of the Meeting, Donald McCaffrey, President and Chief Executive Officer, will provide a corporate update presentation.
It is highly recommended to access the webcast over the Internet using the following link: http://services.choruscall.ca/links/resverlogixagm20201222.html A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.
If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-403-351-0324 (International Toll). Callers should dial-in at least 15 min prior to the scheduled start time.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.
BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on:
- Twitter: @Resverlogix_RVX
- LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information related to the role of apabetalone in the treatment of patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.